Tag: Adaptive Immunity
Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Introduction Immune checkpoint inhibitors (ICIs) can yield remarkable clinical responses in subsets of patients with solid tumors, but they also commonly cause immune-related adverse events (irAEs). The predictive features of clinically severe irAEs leading to cessation of ICIs have yet to be established. Given the similarities between irAEs and autoimmune diseases, we sought to investigate… Continue reading Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Background B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell immunotherapy has shown promising results in the treatment of relapsed or refractory multiple myeloma (R/RMM). This study presents the updated long-term outcomes from our center. Methods Between July 30, 2018, and September 27, 2023, 141 patients with R/RMM who received BCMA CAR-T therapy were enrolled.… Continue reading Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein
Nasal production of IL-26 involving T cells in smokers with and without COPD
Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
Abstract Hepatitis E virus (HEV) poses a significant risk to human health. In Europe, the majority of HEV infection are caused by the zoonotic genotype 3 (HEV-3), which can cause chronic hepatitis E in immunocompromised patients and those with pre-existing liver disease, and may eventually develop into fatal liver cirrhosis. In this study, we examined… Continue reading Therapeutic treatment of hepatitis E virus infection in pigs with a neutralizing monoclonal antibody
[ASAP] Construction of Bispecific T-Cell Engager Radiotracer and Its Micro-PET Evaluation in Pancreatic Cancer
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.5c00072
Personalized Vaccines and Beyond: Confronting the Complex Biology of Kidney Cancer
Breakthroughs in kidney cancer research, including new insights into the tumor-immune microenvironment and the identification of metabolic vulnerabilities, are reshaping the future of treatment, creating opportunities for therapies tailored specifically to individual patients. These cutting-edge developments in personalized vaccines targeting tumor-specific mutations, novel cell therapies, and biomarkers that can predict treatment responses, could help to… Continue reading Personalized Vaccines and Beyond: Confronting the Complex Biology of Kidney Cancer
Deep mutationally scanned CHIKV E3/E2 virus library maps viral amino acid preferences and predicts viral escape mutants of neutralizing CHIKV antibodies
Fusion proteins enable the creation of monoclonal antibodies
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to advance research projects. Even with significant expansion in the global market for antibodies used in clinical care and research, scientists recognize that there is… Continue reading Fusion proteins enable the creation of monoclonal antibodies